Jaguar health shares comments from fda's december 21 press release about conditional approval of canalevia-ca1 (crofelemer) for treatment for chemotherapy-induced diarrhea (cid) in dogs

By prescription only, canalevia™-ca1 is a canine-specific formulation of crofelemer, jaguar's novel, oral plant-based product sustainably harvested from the croton lechleri tree san francisco, ca / accesswire / december 22, 2021 / jaguar health, inc. (nasdaq:jagx) today shared the following quote from the press release the u.s. food and drug administration (fda) issued december 21, 2021: "diarrhea is a common side effect of chemotherapy in dogs, which can be so severe that cancer treatment must be halted. chemotherapy drugs often have potential side effects, but, unlike in human medicine where patients may be willing to tolerate some discomfort in exchange for a potential cure, the primary purpose of cancer treatment in dogs and other pets is to extend survival without sacrificing quality of life and comfort," said steven m.
JAGX Ratings Summary
JAGX Quant Ranking